[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100594048":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":28,"centralContacts":29,"locations":39,"responsibleParty":60,"collaborators":28,"id":62,"slug":63,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":28,"eligibilityCriteria":68,"healthyVolunteers":64,"sex":69,"minAge":70,"maxAge":28,"enrollmentInfo":71,"targetDuration":28,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":80,"overallStatus":42,"whyStopped":28,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"Phramongkutklao College of Medicine and Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Once-Daily Dosing Group","ACTIVE_COMPARATOR","Participants will receive ferrous fumarate 200 mg, taken orally once daily for 8 weeks. This arm represents the standard dosing regimen for treating iron deficiency anemia (IDA). Participants will be monitored at baseline, Week 4, and Week 8 for blood counts, iron parameters, and adverse effects. Medication adherence will be assessed using pill counts.",[13],"Drug: Ferrous Fumarate Oral Tablet",{"label":15,"type":16,"description":17,"interventionNames":18},"Alternate-Day Dosing Group","EXPERIMENTAL","Participants will receive ferrous fumarate 400 mg (two 200 mg tablets), taken orally on alternate days for 8 weeks. This dosing strategy is being evaluated for improved iron absorption and fewer gastrointestinal side effects compared to daily dosing. Participants will be monitored at baseline, Week 4, and Week 8 for blood counts, iron parameters, and adverse effects. Medication adherence will be assessed using pill counts.",[13],[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Ferrous Fumarate Oral Tablet","Ferrous fumarate oral tablet 200 mg is an iron supplement used for the treatment of iron deficiency anemia (IDA). In this study, it is administered as either one tablet daily (OD group) or two tablets on alternate days (AD group), with a treatment duration of 8 weeks. The goal is to compare the efficacy and tolerability of alternate-day dosing versus standard once-daily dosing.",[15,9],[26,27],"Ferrous Fumarate 200 mg tablet","Oral iron supplement",null,[30,35],{"name":31,"role":32,"phone":33,"phoneExt":28,"email":34},"Tanapun Thamgrang, Doctor of Medicine","CONTACT","66859930142","tanapun.tham@pcm.ac.th",{"name":36,"role":32,"phone":37,"phoneExt":28,"email":38},"Aticha Kraiput, Doctor of Medicine","66862849871","aticha.kr18@gmail.com",[40],{"facility":41,"status":42,"city":43,"state":28,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"Phramongkutklao Hospital","RECRUITING","Bangkok","10400","Thailand","TH",{"type":48,"coordinates":49},"Point",[50,51],100.50144,13.75398,{"lat":51,"lon":50},[54,55,56,58],{"name":31,"role":32,"phone":33,"phoneExt":28,"email":34},{"name":36,"role":32,"phone":37,"phoneExt":28,"email":38},{"name":36,"role":57,"phone":28,"phoneExt":28,"email":28},"PRINCIPAL_INVESTIGATOR",{"name":31,"role":59,"phone":28,"phoneExt":28,"email":28},"SUB_INVESTIGATOR",{"type":61,"investigatorFullName":28,"investigatorTitle":28,"investigatorAffiliation":28,"oldNameTitle":28,"oldOrganization":28},"SPONSOR","100594048","alternative-vs-once-daily-oral-iron-supplementation-in-iron-deficiency-anemia-ida-100594048",false,"NCT07014371","Alternative vs. Once-Daily Oral Iron Supplementation in Iron Deficiency Anemia (IDA)","Alternative vs. Once-Daily Oral Iron Supplementation in Iron Deficiency Anemia (IDA): A Multicenter, Randomized, Open-Label, Non-Inferiority Trial","Inclusion Criteria:\n\n* Male or female patients aged ≥20 years diagnosed with iron deficiency anemia, defined as: hemoglobin (Hb) \\\u003C13 g\u002FdL in males or \\\u003C12 g\u002FdL in females, and ferritin \\\u003C50 ng\u002FmL or transferrin saturation (TSAT) \\\u003C20%.\n* No iron supplementation within the past 3 months.\n\nExclusion Criteria:\n\n* Hemodynamic instability (e.g., acute bleeding or hypotension).\n* Severe heart failure (New York Heart Association \\[NYHA\\] Class III-IV) or other active cardiac diseases.\n* Active malignancy or history of cancer within the past 3 years (except non-melanoma skin cancer).\n* Pregnancy or breastfeeding.\n* Chronic liver disease including cirrhosis (Child-Pugh class B or C).\n* Chronic kidney disease (estimated glomerular filtration rate \\[eGFR\\] \\\u003C60 mL\u002Fmin\u002F1.73 m²).\n* Clinically significant thalassemia or hemoglobinopathies.\n* Ongoing infection or chronic inflammatory diseases (e.g., rheumatoid arthritis, inflammatory bowel disease).\n* Malabsorption disorders (e.g., history of bariatric surgery).\n* Red blood cell transfusion within the past 3 months.\n\nWithdrawal Criteria\n\n* Withdrawal of informed consent.\n* Severe adverse events requiring permanent discontinuation of study medication.\n* Investigator's judgment that continued participation poses a safety risk.\n* Non-adherence to study medication (compliance \\\u003C 75%).\n\nTreatment Failure\n\n\\- Increase in hemoglobin level of \\\u003C 1 g\u002FdL at Week 4 or Week 8 compared with baseline.","ALL","20 Years",{"count":72,"type":73},114,"ESTIMATED","INTERVENTIONAL",[76],"NA","The goal of this clinical trial is to compare the effectiveness and tolerability of two different oral iron regimens in adults with iron deficiency anemia (IDA). The main questions it aims to answer are:\n\nIs alternate-day oral iron supplementation as effective as once-daily dosing in improving hemoglobin levels?\n\nWhat are the side effects associated with each dosing regimen?\n\nResearchers will compare once-daily vs. alternate-day oral ferrous fumarate to evaluate whether alternate-day dosing is non-inferior in terms of hematologic response, with fewer adverse effects.\n\nParticipants will:\n\nBe randomly assigned to take ferrous fumarate 200 mg once daily or 400 mg on alternate days for 8 weeks\n\nUndergo blood tests and clinical assessments at baseline, Week 4, and Week 8\n\nReport any side effects and bring remaining pills to evaluate medication adherence\n\nThis is a multicenter, randomized, open-label, non-inferiority trial conducted in adults aged 20 years or older with IDA.",[79],"Iron Deficiency Anemia Treatment",[81,82,83,84],"Iron deficiency anemia","Ferrous fumarate","Alternate day dosing","Hemoglobin","2026-01-05",{"date":87,"type":88},"2026-01-07","ACTUAL",{"date":90,"type":88},"2025-06-09",{"date":92,"type":73},"2027-12-31",{"name":5,"class":6},1]